- Home
- GDEV vs TRDA Comparison
GDEV vs TRDA Comparison
Compare GDEV & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEV
- TRDA
- Stock Information
- Founded
- GDEV 2009
- TRDA 2016
- Country
- GDEV Cyprus
- TRDA United States
- Employees
- GDEV N/A
- TRDA N/A
- Industry
- GDEV EDP Services
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- GDEV Technology
- TRDA Health Care
- Exchange
- GDEV Nasdaq
- TRDA Nasdaq
- Market Cap
- GDEV 266.7M
- TRDA 233.5M
- IPO Year
- GDEV N/A
- TRDA 2021
- Fundamental
- Price
- GDEV $17.48
- TRDA $5.28
- Analyst Decision
- GDEV Buy
- TRDA Strong Buy
- Analyst Count
- GDEV 1
- TRDA 3
- Target Price
- GDEV $70.00
- TRDA $25.67
- AVG Volume (30 Days)
- GDEV 4.3K
- TRDA 234.2K
- Earning Date
- GDEV 11-13-2025
- TRDA 11-04-2025
- Dividend Yield
- GDEV N/A
- TRDA N/A
- EPS Growth
- GDEV 12.96
- TRDA N/A
- EPS
- GDEV 2.56
- TRDA N/A
- Revenue
- GDEV $425,112,000.00
- TRDA $79,476,000.00
- Revenue This Year
- GDEV N/A
- TRDA N/A
- Revenue Next Year
- GDEV $11.69
- TRDA N/A
- P/E Ratio
- GDEV $6.83
- TRDA N/A
- Revenue Growth
- GDEV N/A
- TRDA N/A
- 52 Week Low
- GDEV $8.60
- TRDA $4.93
- 52 Week High
- GDEV $42.76
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- GDEV 66.26
- TRDA 42.86
- Support Level
- GDEV $14.52
- TRDA $5.08
- Resistance Level
- GDEV $18.17
- TRDA $5.53
- Average True Range (ATR)
- GDEV 1.05
- TRDA 0.26
- MACD
- GDEV 0.37
- TRDA 0.02
- Stochastic Oscillator
- GDEV 90.00
- TRDA 18.87
About GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.